Patents by Inventor Bruce N. Ames
Bruce N. Ames has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7964587Abstract: Anti-inflammatory compositions include medicaments comprising predetermined amounts of a phytyl substituted chromanol and a prostaglandin E2 inhibitor, wherein: said medicament is in unit dosage form suitable for pharmaceutical administration; said phytyl substituted chromanol is a gamma-tocopherol, delta-tocopherol, gamma-tocotrienol or delta-tocotrienol; said PGE2 inhibitor is a non-steroidal anti-inflammatory drug or an omega-3 fatty acid, such as docosahexaenoic acid and eicosapentaenoic acid.Type: GrantFiled: June 22, 2005Date of Patent: June 21, 2011Assignee: Children's Hospital & Research Center at OaklandInventors: Bruce N. Ames, Qing Jiang
-
Patent number: 7527978Abstract: The invention is a method for analyzing immature reticulocytes for the presence of micronuclei. The method includes reticulocyte enrichment, fluorescent labeling, micronuclei staining, and analysis using single-laser flow cytometry. The invention also includes kits containing reagents to use in the method.Type: GrantFiled: October 7, 2004Date of Patent: May 5, 2009Assignee: Children's Hospital & Research Center at OaklandInventors: Tal Offer, Emily Ho, Bruce N. Ames, Frans Kuypers
-
Publication number: 20080268537Abstract: The invention provides pharmaceutical compositions comprising primary N-hydroxylamines and related therapeutic, prophylactic, diagnostic and screening methods. The pharmaceutical compositions generally comprise a pharmaceutical composition comprising an orally administrable effective unit solid dosage of a primary N-hydroxylamine or a pharmaceutically acceptable salt thereof and substantially free of a nitrone corresponding to the hydroxylamine.Type: ApplicationFiled: July 7, 2008Publication date: October 30, 2008Applicant: The Regents of the University of CaliforniaInventors: Bruce N. Ames, Hani Atamna
-
Patent number: 7399784Abstract: Anti-obesity compositions include medicaments comprising predetermined amounts of a phytyl substituted chromanol and an obesity-promoting drug, wherein: said medicament is in unit dosage form suitable for pharmaceutical administration; said phytyl substituted chromanol is a gamma-tocopherol, delta-tocopherol, alpha-tocotrienol, gamma-tocotrienol or delta-tocotrienol; said obesity-promoting drug is a corticosteroid or an anti-diabetes drug such as a hypoglycemic drug, starch blocker, glucose production blocker or insulin sensitizer.Type: GrantFiled: November 26, 2002Date of Patent: July 15, 2008Assignee: Children's Hospital & Research Center at OaklandInventors: Bruce N. Ames, Qing Jiang
-
Patent number: 7030154Abstract: A method of stabilizing R-?-lipoic acid includes combining R-?-lipoic acid with nicotinamide in a weight ratio between about 10:4 to about 10:8. A composition for treating oxidative stress includes R-?-lipoic acid and nicotinamide in a weight ratio of between about 10:4 and about 10:8.Type: GrantFiled: June 5, 2003Date of Patent: April 18, 2006Assignee: Juvenon, Inc.Inventor: Bruce N. Ames
-
Patent number: 7026338Abstract: Pharmaceutical nitrone comprise condensates of an N-hydroxylamine and a physiological aldehyde, providing improved delivery and absorption, enhanced stability and reduced toxicity. Preferred physiological aldehydes are subject to endogenous cellular uptake transport, and include pyridoxal, pyridoxal phosphate, and heme-A. Essentially any physiologically compatible and pharmaceutically active hydroxylamine moiety may be incorporated, such as hydroxylamine moieties of prior pharmaceutical nitrones, and known pharmaceutically active hydroxylamines.Type: GrantFiled: May 11, 2004Date of Patent: April 11, 2006Assignee: Children's Hospital Research Center at OaklandInventors: Bruce N. Ames, Hani Atamna
-
Publication number: 20040110729Abstract: The invention provides pharmaceutical compositions comprising primary N-hydroxylamines and related therapeutic, prophylactic, diagnostic and screening methods. The pharmaceutical compositions generally comprise a pharmaceutical composition comprising an orally administrable effective unit solid dosage of a primary N-hydroxylamine or a pharmaceutically acceptable salt thereof and substantially free of a nitrone corresponding to the hydroxylamine.Type: ApplicationFiled: November 25, 2003Publication date: June 10, 2004Inventors: Bruce N. Ames, Hani Atamna
-
Publication number: 20040102420Abstract: The invention provides pharmaceutical compositions comprising primary N-hydroxylamines and related therapeutic, prophylactic, diagnostic and screening methods. The pharmaceutical compositions generally comprise a pharmaceutical composition comprising an orally administrable effective unit solid dosage of a primary N-hydroxylamine or a pharmaceutically acceptable salt thereof and substantially free of a nitrone corresponding to the hydroxylamine.Type: ApplicationFiled: November 13, 2003Publication date: May 27, 2004Inventors: Bruce N. Ames, Hani Atamna
-
Publication number: 20040102385Abstract: Anti-obesity compositions include medicaments comprising predetermined amounts of a phytyl substituted chromanol and an obesity-promoting drug, wherein: said medicament is in unit dosage form suitable for pharmaceutical administration; said phytyl substituted chromanol is a gamma-tocopherol, delta-tocopherol, alpha-tocotrienol, gamma-tocotrienol or delta-tocotrienol; said obesity-promoting drug is a corticosteroid or an anti-diabetes drug such as a hypoglycemic drug, starch blocker, glucose production blocker or insulin sensitizer.Type: ApplicationFiled: November 26, 2002Publication date: May 27, 2004Applicant: Children's Hospital Research Center at OaklandInventors: Bruce N. Ames, Qing Jiang
-
Publication number: 20040102421Abstract: Anti-inflammatory compositions include medicaments comprising predetermined amounts of a phytyl substituted chromanol and a prostaglandin E2 inhibitor, wherein: said medicament is in unit dosage form suitable for pharmaceutical administration; said phytyl substituted chromanol is a gamma-tocopherol, delta-tocopherol, gamma-tocotrienol or delya-tocotrienol; said PGE2 inhibitor is a non-steroidal anti-inflammatory drug or an omega-3 fatty acid, such as docosahexaenoic acid and eicosapentaenoic acid.Type: ApplicationFiled: November 21, 2002Publication date: May 27, 2004Applicant: Children's Hospital Research Center at OaklandInventors: Bruce N. Ames, Qing Jiang
-
Publication number: 20040044046Abstract: A method of stabilizing R-&agr;-lipoic acid includes combining R-&agr;-lipoic acid with nicotinamide in a weight ratio between about 10:4 to about 10:8. A composition for treating oxidative stress includes R-&agr;-lipoic acid and nicotinamide in a weight ratio of between about 10:4 and about 10:8.Type: ApplicationFiled: June 5, 2003Publication date: March 4, 2004Inventor: Bruce N. Ames
-
Publication number: 20030153535Abstract: The invention provides pharmaceutical compositions comprising primary N-hydroxylamines and related therapeutic, prophylactic, diagnostic and screening methods. The pharmaceutical compositions generally comprise a pharmaceutical composition comprising an orally administrable effective unit solid dosage of a primary N-hydroxylamine or a pharmaceutically acceptable salt thereof and substantially free of a nitrone corresponding to the hydroxylamine.Type: ApplicationFiled: October 20, 2001Publication date: August 14, 2003Applicant: The Regents of the University of CaliforniaInventors: Bruce N. Ames, Hani Atamna
-
Patent number: 6455589Abstract: The invention provides pharmaceutical compositions comprising primary N-hydroxylamines and related therapeutic, prophylactic, diagnostic and screening methods. The pharmaceutical compositions generally comprise a pharmaceutical composition comprising an orally administrable effective unit solid dosage of a primary N-hydroxylamine or a pharmaceutically acceptable salt thereof and substantially free of a nitrone corresponding to the hydroxylamine.Type: GrantFiled: October 28, 1999Date of Patent: September 24, 2002Assignee: The Regents of the University of CaliforniaInventors: Bruce N. Ames, Hani Atamna
-
Patent number: 5916912Abstract: The metabolic rate of aged cells of a mammalian host is enhanced without a concomitant increase in metabolic production of reactive oxygen species by orally administering to the host an effective dosage of a carnitine, such as acetyl-L-carnitine, and a mitochondrially active antioxidant, such as lipoic acid.Type: GrantFiled: June 16, 1997Date of Patent: June 29, 1999Assignee: The Regents of the University of CaliforniaInventors: Bruce N. Ames, Tory M. Hagen
-
Patent number: 5869258Abstract: Six sets of Salmonella typhimurium strains are provided, all strains having low spontaneous mutation rates, and each set being sensitive to and diagnostic of one of the six possible base substitutions in DNA. Also provided are methods for making and using these S. typhimurium strains to detect, and establish the type of specific base substitution mutation induced by, mutagenic agents.Type: GrantFiled: May 28, 1997Date of Patent: February 9, 1999Assignee: The Regents of the University of CaliforniaInventors: Pauline Gee, Dorothy M. Maron, Bruce N. Ames
-
Patent number: 5681737Abstract: Six sets of Salmonella typhimurium strains are provided, all strains having low spontaneous mutation rates, and each set being sensitive to and diagnostic of one of the six possible base substitutions in DNA. Also provided are methods for making and using these S. typhimurium strains to detect, and establish the type of specific base substitution mutation induced by, mutagenic agents.Type: GrantFiled: October 15, 1993Date of Patent: October 28, 1997Assignee: The Regents of the University of CaliforniaInventors: Pauline Gee, Dorothy M. Maron, Bruce N. Ames